The FDA Said No to Leucovorin for Autism. Here Is Why That Matters.

When political figures make health claims about autism, families listen. That is not a flaw in families. It is a flaw in the information environment.

In early 2026, government officials claimed leucovorin, a drug approved for a rare genetic disorder called cerebral folate deficiency, could be a treatment for hundreds of thousands of autistic children. The FDA approved leucovorin for cerebral folate deficiency. It did not approve it for autism.

That distinction matters.

What the Research Actually Shows

A handful of small trials have suggested leucovorin might benefit a specific subset of autistic children with cerebral folate antibodies. The keyword is small. These were not large randomized controlled trials. The evidence base was preliminary at best.

Cerebral folate deficiency is a distinct condition. Some autistic people have it. Most do not. Conflating a treatment for a specific comorbid condition with a treatment for autism itself is not a minor error. It is a fundamental misrepresentation.

The FDA held the line. When the evidence is not there, approval does not happen. That process exists precisely to protect families from hope dressed as science.

The Real Harm: Documented

What makes this story more than a policy dispute is what came next. New research from Medscape published in March 2026 documented that the political claims had already changed clinical behavior.

Prenatal Tylenol orders in emergency rooms dropped measurably after political statements linking it to autism. Leucovorin prescriptions for children surged. Families and clinicians changed their behavior based on unverified claims from a press conference, not from clinical evidence.

That is the concrete harm of medical misinformation. Not hypothetical. Documented.

Why WeBearish Tracks This

WeBearish is not a medical authority and does not give medical advice. What we do is make sure families have access to accurate information about where the science actually stands.

The pattern here is one the autism community has seen before: a promising early signal, political amplification, widespread uptake, and eventual correction after real-world harm. The correction takes years. The uptake takes days.

Families deserve better than that timeline.

The Acceptance Framework Holds

None of this changes the fundamental WeBearish position. Autism is not a disease requiring pharmaceutical correction. The children these treatments are aimed at are not broken. The goal of any intervention should be improving quality of life and wellbeing for the autistic person, not making them appear less autistic.

Legitimate science, when it produces real tools that help autistic people on their own terms, is worth knowing about. Political claims dressed as science, running ahead of the evidence, cause harm. The distinction is always worth making.

---

**Sources**

- FDA leucovorin approval and autism statement, March 2026

- Medscape research on political misinformation and clinical behavior, March 2026

- STAT News, Washington Post, CNN coverage of leucovorin decision

**More from WeBearish**

- [The Neurodiversity Movement](/neurodiversity-movement-history) — Where it came from and where it is going

- [Autism Awareness vs. Acceptance](/autism-acceptance-vs-awareness-practical) — What the difference looks like in practice

- [Join the WeBearish Community](/community) — No tragedy narratives.